Figure 7. Kiss1 shRNA knockdown in vivo in livers of in HFD and Leprdb/db mice de-represses GSIS and glucose tolerance.
HFD mice: Panels A–H
Leprdb/db mice: Panels I–P
A, I Representative liver IB of pCREB, total CREB and kisspeptin1 3 days after treatment with Adv-scr or -Kiss1 shRNA. Liver pCREB is not affected and liver kisspeptin1 protein is reduced by Kiss1 knockdown.
B, J qRT-PCR of Kiss1 in livers 3 days after treatment with Adv-scr or -Kiss1 shRNA. Adv-Kiss1 shRNA downregulates liver Kiss1 mRNA levels as compared to Adv-scr shRNA treatment (mean±SEM, *P<0.05).
C, K Plasma kisspeptin1 levels 3 days after treatment with Adv-scr or -Kiss1 shRNA. Liver Kiss1 knockdown reduces plasma kisspeptin1 (mean±SEM, *P<0.05).
D, L Plasma glucagon levels 3 days after treatment with Adv-scr or -Kiss1 shRNA. Liver Kiss1 knockdown does not change plasma glucagon levels (mean±SEM0.
E, M Caloric intake in during 3 days after treatment with Adv-scr or -Kiss1 shRNA. Caloric intake is unaffected by Kiss1 knockdown (mean±SEM).
F, N ipGTT 3 days after treatment with Adv-scr or -Kiss1 shRNA. GT is improved after Kiss1 knockdown (mean±SEM, *P<0.05).
G, O GSIS during ipGTT 3 days after treatment with Adv-scr or -Kiss1 shRNA. GSIS is improved after Kiss1 knockdown (mean±SEM, *P<0.05).
H, P ipITT 3 days after treatment with Adv-scr or -Kiss1 shRNA. Insulin tolerance is not different after Kiss1 knockdown.